Skip to main content

Table 2 Case and sub-cohort group characteristics, with sub-cohort rate of HHV-8 seropositivity, according to baseline characteristic

From: A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago

  Cases (n = 96) Sub-cohort (n = 415) Sub-cohort HHV-8 Pos  
Characteristic n1 Col % n1 Col % n1 Row % p-value2
Demographic        < .0001
   Age (years)        
40-49 12 12.5 200 48.2 7 3.5  
50-59 37 38.5 110 26.5 15 13.6  
60-81 47 49.0 105 25.3 24 22.9  
   Education    (2)   (0)   0.83
≤11 years 77 80.2 318 77.0 36 11.3  
12+ years 19 19.8 95 23.0 10 10.5  
   Marital status        0.48
ever married 82 85.4 336 81.0 39 11.6  
never married 14 14.6 79 19.0 7 8.9  
Family history of ...        
   Prostate cancer        0.80
missing 5 5.2 32 7.7 4 12.5  
yes 5 5.2 27 6.5 2 7.4  
no 86 89.6 356 85.8 40 11.2  
History of ...        
   Smoking    (1)   (0)   0.029
yes 34 35.4 170 41.1 12 7.1  
no 62 64.6 244 58.9 34 13.9  
   Benign prostatic hypertrophy (3)   (8)   (0)   0.039
yes 10 10.8 25 6.1 6 24.0  
no 83 89.2 382 93.9 40 10.5  
Entry prostate cancer screen        
   PSA (ng/mL)        0.010
0.0-0.9 7 7.3 197 47.5 15 7.6  
1.0-1.9 27 28.1 140 33.7 17 12.1  
2.0-3.9 36 37.5 55 13.3 7 12.7  
≥ 4.0 26 27.1 23 5.5 7 30.4  
   DRE        0.34
missing 4 4.2 48 11.6 4 8.3  
positive 29 30.2 54 13.0 9 16.7  
negative 63 65.6 313 75.4 33 10.5  
   DRE positive and/or PSA ≥ 4 ng/mL        0.009
yes 42 43.8 70 16.9 14 20.0  
no 54 56.3 345 83.1 32 9.3  
Study-specific        
   HHV-8 sero-status        
positive 17 17.7 46 11.1    
negative 79 82.3 369 88.9    
  1. PSA - prostate-specific antigen, DRE - digital rectal examination, HHV-8 - human herpesvirus 8
  2. 1. Numbers in parentheses indicate missing data
  3. 2. Statistical significance (chi-square) of differences in HHV-8 seropositivity according to baseline characteristic